CIRIUM
29.5.2024 17:01:25 CEST | Business Wire | Press release
Cirium, the leader in aviation analytics, has introduced the industry’s most precise independent standard for measuring aircraft emissions and fuel burn.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529697359/en/
Cirium Emerald Sky (Photo: Business Wire)
This groundbreaking and revolutionary methodology analyses each flight's specific aircraft type and design specifications, combined with real-time operational data and flight conditions, ensuring unparalleled accuracy and reliability in emission tracking.
Cirium’s Emerald Sky seamlessly integrates Cirium’s comprehensive data, advanced analytics, and innovative techniques to achieve unmatched precision in measuring both current and forecasted CO2 flight emissions.
Unlike traditional carbon calculators that depend on broad estimates and loose assumptions – such as using pre-planned routes instead of actual flown paths, and ignoring variables like wind speed and direction – Emerald Sky provides emissions results based on the seat in a specific class of service and sets a new standard in aircraft emissions measurement.
Jeremy Bowen, CEO of Cirium, said: “Cirium’s mission is to establish the industry standard for accurate fuel burn and carbon emissions data to empower the aviation sector to deliver on its sustainability targets.
“Cirium’s world-beating methodology even considers each aircraft’s typical operating weight, passengers and baggage, cargo payload, and degradation in engine efficiency over time to provide the most accurate data available to help achieve aviation’s ambitious sustainability goals.”
Endorsed by airlines and industry stakeholders, Emerald Sky offers users access to both historical data for up to five years and predictive carbon footprint for the upcoming 12 months.
This robust data enables precise, independent assessment of each aircraft's emissions, supporting more informed decision-making across the aviation sector. This ensures more precise flight emission reporting, which is critically important in meeting current and future climate regulations.
With superior data, Emerald Sky enables users to:
- Undertake a thorough assessment of sustainable aircraft and fleet options
- Identify opportunities for aircraft upgrades
- Promote eco-friendly travel by providing sustainable flight options
- Comply with emissions regulations and ESG reporting requirements
- Evaluate investments in aviation carbon offset and elimination programs
- Forecast the demand for sustainable aviation fuels (SAF)
- Identify opportunities for aircraft upgrades.
In a world with an immense focus on the environmental impact of aviation, Emerald Sky's rigorous approach is essential for accurate reporting and responsible aviation practices.
Emerald Sky supports Cirium’s ongoing mission to make a meaningful positive impact on the future of aviation and the environment, alongside the industry’s Net Zero targets.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth. Cirium® is part of LexisNexis® Risk Solutions, a RELX business. RELX is a global provider of information-based analytics and decision tools for professional and business customers.
For further information please follow Cirium updates on LinkedIn or Twitter or visit cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529697359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
